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Summary
Background As trials of 5 years of tamoxifen in early breast cancer mature, the relevance of hormone receptor 
measurements (and other patient characteristics) to long-term outcome can be assessed increasingly reliably. We 
report updated meta-analyses of the trials of 5 years of adjuvant tamoxifen. 
Methods We undertook a collaborative meta-analysis of individual patient data from 20 trials (n=21 457) in early breast 
cancer of about 5 years of tamoxifen versus no adjuvant tamoxifen, with about 80% compliance. Recurrence and 
death rate ratios (RRs) were from log-rank analyses by allocated treatment.
Findings In oestrogen receptor (ER)-positive disease (n=10 645), allocation to about 5 years of tamoxifen 
substantially reduced recurrence rates throughout the ﬁ rst 10 years (RR 0·53 [SE 0·03] during years 0–4 and 
RR 0·68 [0·06] during years 5–9 [both 2p<0·00001]; but RR 0·97 [0·10] during years 10–14, suggesting no further 
gain or loss after year 10). Even in marginally ER-positive disease (10–19 fmol/mg cytosol protein) the recurrence 
reduction was substantial (RR 0·67 [0·08]). In ER-positive disease, the RR was approximately independent of 
progesterone receptor status (or level), age, nodal status, or use of chemotherapy. Breast cancer mortality was 
reduced by about a third throughout the ﬁ rst 15 years (RR 0·71 [0·05] during years 0–4, 0·66 [0·05] during years 
5–9, and 0·68 [0·08] during years 10–14; p<0·0001 for extra mortality reduction during each separate time period). 
Overall non-breast-cancer mortality was little aﬀ ected, despite small absolute increases in thromboembolic 
and uterine cancer mortality (both only in women older than 55 years), so all-cause mortality was 
substantially reduced. In ER-negative disease, tamoxifen had little or no eﬀ ect on breast cancer recurrence 
or mortality.
Interpretation 5 years of adjuvant tamoxifen safely reduces 15-year risks of breast cancer recurrence and 
death. ER status was the only recorded factor importantly predictive of the proportional reductions. Hence, the 
absolute risk reductions produced by tamoxifen depend on the absolute breast cancer risks (after any chemotherapy) 
without tamoxifen.
Funding Cancer Research UK, British Heart Foundation, and Medical Research Council.
Introduction
In oestrogen receptor (ER)-positive early breast 
cancer, endocrine treatment reduces the recurrence 
and mortality rates, whether or not chemotherapy is 
also given.1 Adjuvant tamoxifen is a major endocrine 
treatment option, particu larly for women who still 
have signiﬁ cant ovarian oestro genic activity that 
cannot be controlled by aromatase inhibitors. In trials 
of about 5 years of adjuvant tamoxifen versus no 
tamoxifen for early breast cancer, follow-up now 
extends well into the second decade since 
randomisation. This extended follow-up allows 
improved assessment of long-term eﬀ ects on breast 
cancer mortality and other mortality, and of the eﬀ ects 
of endocrine therapy in disease that is only weakly 
hormone-receptor positive. We report updated meta-
analyses of data for individual women in these trials, 
relating the eﬀ ects of tamoxifen to quantitative 
measurements of hormone receptor levels, use of 
chemo therapy, and other factors.
Methods
Data collection
Trial identiﬁ cation and data handling procedures have 
been described previously.1–3 We sought updated data 
from each randomised trial in women with early breast 
cancer of adjuvant tamoxifen versus not, in which only 
tamoxifen diﬀ ered (ie, unconfounded trials). Trials in 
women with ductal carcinoma in situ were excluded. 
Results of only 1–2 years of adjuvant tamoxifen 
(n=33 000 women ran domly assigned) are essentially 
unchanged since pre viously reported,1 and are given only 
in webappendix p 2. In this Article, we report the trials of 
longer tamoxifen durations (described as about 5 years of 
tamoxifen).4–26 Most trials were of exactly 5 years of 
tamoxifen,4–16 four were of only 3 years,17–21 one re-
randomised some partici pants at year 2 to stop or 
continue to year 5 (with all re-randomised patients 
remaining in the analyses),22 and two re-randomised 
some at year 5 to stop or continue to year 1023–26 
(webappendix pp 18–36). 
See Online for webappendix
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As in previous meta-analyses from the Early Breast 
Cancer Trialists’ Collaborative Group (EBCTCG), infor-
mation was sought for each patient on date of random-
isation, allocated treatment, age, menopausal status, 
tumour diameter, grade, spread to locoregional lymph 
nodes, and any ER or progesterone receptor (PR) 
measurements, mostly in femtomoles of receptor protein 
per mg cytosol protein (fmol/mg). Values of 10 fmol/mg or 
greater were, as before,1 described as receptor positive, with 
lower values described interchangeably as receptor negative 
or receptor poor. Other receptor-positive or receptor-poor 
measurements (including the few measured by immuno-
histochemistry) were those given only qualitatively. 
Information was generally unavailable on assay methods 
and on whether assays were done centrally or at local 
hospitals. Within-trial receptor measurement distribution 
(0, 1–3, 4–9, 10–19, 20–29, 30–49, 50–99, 100–199, and 
≥200 fmol/mg) was inspected to help to assess assay 
quality, with results showing no obvious anomalies (data 
not shown). 
Follow-up was updated on dates of ﬁ rst recurrence of 
any breast cancer (locoregional, contralateral [either 
could include new onset], or distant), other second 
primary cancer, and death. Summary information on a 
whole-trial basis (rather than an individual basis) was 
sought on approximate levels of compliance with the 
treatment allocation 2–3 years after randomisation.
Statistical analysis 
Methods of analysis were as previously described,1–3 
except that analyses were stratiﬁ ed by trial, age at entry 
(<45, 45–54, 55–69, and ≥70 years), nodal status (node-
negative by local criteria, 1–3 nodes positive after axillary 
clearance, ≥4 nodes positive, other or unknown), and ER 
status (poor, positive, unknown), deﬁ ning 4×4×3 strata. 
Log-rank statistics and their variances were calculated 
separately in each stratum and summed, yielding the 
stratiﬁ ed result. To avoid over-stratiﬁ cation, subgroup 
analyses of tumour grade or diameter were stratiﬁ ed by 
only two categories of age (≥50 years, other [or unknown]) 
and nodal status (negative, other [or unknown]) and three 
of ER status, deﬁ ning 2×2×3 strata. 
Survival curves show time to recurrence, breast cancer 
mortality, and any mortality. Yearly rates of breast cancer 
mortality assess the excess mortality when the mortality 
rate in women without recurrence is subtracted from the 
overall mortality rate in all women. Correspondingly, rate 
ratios (RRs) for breast cancer mortality are estimated 
from log-rank analyses of mortality with recurrence, 
obtained by subtraction of the log-rank analyses of 
mortality without recurrence (ie, censored at recurrence) 
from those of all mortality. 
If a log-rank statistic (O−E) has variance V, then, 
deﬁ ning z=(O−E)/√V and b=(O−E)/V, RR=exp(b), the 
event rate ratio, is taken to have SE=(RR−1)/z and 95% CI 
exp(b±1·96/√V). Results cite RR (and its SE). p values 
(two sided) are obtained by comparing z with a standard 
normal distribution, so z=1·96 yields p=0·05 (described 
as 2p, for consistency with previous reports).
Role of the funding sources
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The secretariat had full access to all 
the data and analyses, and accepts responsibility for this 
report. Final analyses and a draft report were presented 
and discussed at a meeting of many trialists, after which 
a revised report was circulated to all trialists for written 
comment and revised again. The writing committee 
prepared the report and was responsible for the decision 
to submit for publication. 
Results
Information was available for 99% (21 457/21 712) of all 
women known to have been randomly assigned into 
trials of about 5 years of adjuvant tamoxifen (webappendix 
pp 18–35). Although 21 trials started, one6  with 
255 women was terminated early and the records were 
never analysed, and were lost. All women were randomly 
assigned evenly between tamoxifen and control. Six 
major trials described compliance with the tamoxifen 
allocation (75% in NSABP25,26 completed ≥3 years; and 
89% in GROCTA,15 78% in IBCSG,13 82% in ICCG,10 69% 
in NCIC,11 and 86% in SWOG7 [weighted mean 82%] 
completed ≥2 years). Compliance with allocation to 
control was unavailable, but should have been good in 
early trials (although perhaps less good for women with 
ER-positive disease in later trials, undertaken when 
treatment guidelines recommended tamoxifen).
In ER-positive disease, allocation to tamoxifen halved 
the recurrence rate during years 0–4 and reduced it by a 
third during years 5–9 (with little further eﬀ ect after 
year 10), so over all time periods the recurrence rate 
reduction averaged 39% (RR 0·61 [SE 0·03; 2p<0·00001] 
for any recurrence, and RR 0·62 [0·07; 2p<0·00001] for 
contralateral disease incidence). In ER-poor disease, 
however, there was no apparent eﬀ ect on recurrence 
(RR 0·97 [0·05] for any recurrence, 95% CI 0·88–1·07; 
RR 0·94 [0·12] for contralateral disease, 95% CI 
0·73–1·20) (webappendix p 9). Although the overall 
prognosis for ER-poor disease seemed (somewhat 
misleadingly) about as good as that for tamoxifen-treated 
ER-positive disease, this comparison was confounded by 
nodal status and, particularly, by widespread use of 
chemotherapy in ER-poor disease (ﬁ gure 1). 
ER and PR status were strongly associated; PR (when 
measured) was positive in 76% (7378 of 9688) of ER-
positive and only 21% (1236 of 5984) of ER-negative 
(strictly, ER-poor) disease. Given ER status, however, 
PR status was not signiﬁ cantly predictive of response. 
The RR was 0·63 (SE 0·03) for ER-positive PR-positive 
disease and 0·60 (0·05) for ER-positive PR-negative 
disease (both 2p<0·00001). The RR was 0·90 (0·10) for 
ER-negative PR-positive disease (2p=0·35) and 1·03 
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(0·06) for ER-negative PR-negative disease (2p=0·60; 
ﬁ gure 1). 
Analyses of quantitative ER and PR measurements did 
not materially change these ﬁ ndings (ﬁ gure 2). If the ER 
measurement was less than 10 fmol/mg cytosol protein 
(ie, ER-poor disease) there was no apparent beneﬁ t from 
addition of tamoxifen. Even for weakly positive ER, 
however, there was substantial beneﬁ t (RR 0·67 [SE 0·08] 
for ER 10–19 fmol/mg), and the proportional eﬀ ect at 
much higher ER was only slightly better (RR 0·52 [0·07] 
for ER ≥200 fmol/mg, trend in RR with ER [if ER 
≥10 fmol/mg] p=0·002). In ER-positive disease, the PR 
measurements were not predictive of who would respond 
to tamoxifen, so subsequent analyses ignore PR and are 
Figure 1: Relevance of measured ER and PR status to the eﬀ ects of about 5 years of tamoxifen on the 10-year probability of recurrence
Outcome by allocated treatment in trials of about 5 years of adjuvant tamoxifen. Event rate ratio (RR) is from summed log-rank statistics for all time periods. Gain 
(and its SE) is absolute diﬀ erence between ends of graphs. ER=oestrogen receptor. PR=progesterone receptor. O–E=observed minus expected, with variance V.
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limited to the 10 645 women with ER-positive disease, with 
median follow-up in survivors of 13 years (IQR 9–18).
Figure 3 shows the 10-year recurrence risks for women 
with node-negative and node-positive ER-positive disease, 
subdivided by use of chemotherapy. Even if chemotherapy 
was given, tamoxifen was of substantial further beneﬁ t 
(ie, chemotherapy plus tamoxifen was better than 
chemotherapy alone), producing a further reduction of 
about a quarter in 10-year recurrence risk (ﬁ gure 3). 
Figure 4 subdivides the results for ER-positive disease 
according to daily tamoxifen dose tested, use of 
background chemotherapy (present or absent, and if 
present, concurrent or sequential), entry age, nodal status, 
tumour grade (poorly diﬀ erentiated or moderately or well 
diﬀ erentiated), diameter (1–20, 21–50, or >50 mm), site of 
ﬁ rst recurrence (isolated locoregional, contralateral, or 
distant), and time since randomisation (0–1, 2–4, 5–9, or 
≥10 years). Substantial and highly signiﬁ cant recurrence 
Figure 2: Relevance of quantitative ER and PR measurement (fmol/mg cytosol protein) to the tamoxifen versus control recurrence rate ratio
Outcome by allocated treatment in trials of about 5 years of adjuvant tamoxifen. Other ER poor includes ER-negative by immunohistochemistry and ER unspeciﬁ ed, 
but less than 10 fmol/mg. ER=oestrogen receptor. PR=progesterone receptor. O–E=observed minus expected. 
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reductions were recorded in every subgroup (apart from 
the period ≥10 years after entry). Corresponding subgroup 
analyses for breast cancer mortality (ie, mortality rate in 
all women less that in women without recurrence) yielded 
generally similar ﬁ ndings (webappendix p 4), except that 
a substantial mortality reduction continued well beyond 
year 10 (RR during years ≥10 after entry 0·73 [SE 0·07], 
p<0·00001). Thus, the recurrence reduction during 
years 0–9 caused a highly signiﬁ cant reduction in breast 
cancer mortality both during and after years 0–9.
The recurrence reduction seemed somewhat greater in 
trials of higher daily tamoxifen doses (p=0·02 for trend 
between RRs for 20, 30, and 40 mg per day), but we found 
no such dose eﬀ ect for breast cancer mortality 
Figure 3: Relevance of nodal status and of background chemotherapy to the eﬀ ects of tamoxifen on the 10-year probability of recurrence, for ER-positive disease
Outcome by allocated treatment in trials of about 5 years of adjuvant tamoxifen. Event rate ratio (RR) is from summed log-rank statistics for all time periods. Gain 
(and its SE) is absolute diﬀ erence between ends of graphs. ER=oestrogen receptor. PR=progesterone receptor. O–E=observed minus expected, with variance V.
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Figure 4: Subgroup analyses of the tamoxifen versus control recurrence rate ratio, for ER-positive disease 
Outcome by allocated treatment in trials of about 5 years of adjuvant tamoxifen. ER=oestrogen receptor. O–E=observed minus expected, with variance V. 
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712/26 610 (2·7)
41/1512 (2·7)
0/11 (0·0)
753/37 672 (2·0)
348/10 126 (3·4)
355/5097 (7·0)
197/3852 (5·1)
101/2022 (5·0)
201/4285 (4·7)
1351/50 461 (2·7)
647/29 188 (2·2)
771/20 603 (3·7)
78/1462 (5·3)
157/5495 (2·9)
205/34 320 (0·6)
237/54 952 (0·4)
1098/54 960 (2·0)
113/56 714 (0·2)
343/10 229 (3·4)
548/13 434 (4·1)
454/17 258 (2·6)
308/15 631 (2·0)
1653/56 747 (2·9% per year)
(a) Dose (trend χ²=5·4; 2p=0·02)
20 mg per day
30 mg per day
40 mg per day
(b) Background chemotherapy (χ²=7·7; 2p=0·006)
Present
Absent
(c) Background chemotherapy (χ²=2·1; 2p=0·1)
Concurrent
Sequential
Absent
(d) Entry age (years) (trend χ²=5·5; 2p=0·02) 
<45
45–54
55–69
≥70
Age unknown
(e) Nodal status (trend χ²=0·2; 2p=0·7)
N0/N–
N1–3
N4+
Other/unknown
(f) Tumour diﬀerentiation  (χ²=1·1; 2p=0·3)
Poorly diﬀerentiated
Moderately/well
Grade unknown
(g) Tumour diameter (mm) (trend χ²=1·2; 2p=0·3)
1–20 (T1)
21–50 (T2)
>50 (T3/T4)
Other/unknown
(h) Site of ﬁrst recurrence  (χ²=2·1; p=0·4)
Isolated local
Contralateral
Distant/multiple
Unknown
(i) Time since randomisation (years) (trend χ²=43·7; 2p<0·00001)
0–1
2–4
5–9
≥10
               Total
–273·8
–76·6
–83·1
–170·5
–263·1
–81·8
–88·7
–263·1
–105·1
–83·8
–228·8
–15·8
–227·6
–79·8
–93·2
–33·0
–38·5
–48·8
–333·2
–188·2
–169·0
–17·2
–40·5
–74·6
–65·1
–262·4
–31·4
–175·3
–168·0
–82·5
–7·7
–433·5
0·65 (SE 0·03)
0·52 (SE 0·07)
0·54 (SE 0·06)
0·67 (SE 0·04)
0·56 (SE 0·04)
0·62 (SE 0·06)
0·71 (SE 0·05)
0·56 (SE 0·04)
0·63 (SE 0·05)
0·72 (SE 0·05)
0·54 (SE 0·04)
0·50 (SE 0·15)
0·60 (SE 0·04)
0·64 (SE 0·06)
0·56 (SE 0·06)
0·71 (SE 0·09)
0·52 (SE 0·10)
0·61 (SE 0·08)
0·64 (SE 0·03)
0·60 (SE 0·04)
0·66 (SE 0·04)
0·63 (SE 0·03)
0·60 (SE 0·09)
0·54 (SE 0·07)
0·62 (SE 0·07)
0·63 (SE 0·03)
0·61 (SE 0·10)
0·47 (SE 0·05)
0·58 (SE 0·04)
0·68 (SE 0·06)
0·94 (SE 0·09)
0·611 (SE 0·027; 
95% CI 0·57–0·65)
Allocated tamoxifen
Events/woman-years (rate [% per year])Category
Allocated control Log-rank 
O–E
Tamoxifen events
Variance 
of O-E
Tamoxifen : control
Ratio of annual event rates
627·6
118·4
135·4
430·1
451·3
169·2
260·9
451·3
226·9
256·8
374·9
22·8
443·3
180·1
161·3
96·7
58·1
99·3
734·9
365·8
403·5
36·9
78·8
121·7
136·8
558·8
64·1
230·2
304·9
217·6
128·8
881·4
0·25 0·5 1·0 2·0
Tamoxifen better             Tamoxifen worse
Treatment eﬀect 2p<0·00001
99% or 95% CIs
¹
¹
¹
¹
¹
¹
¹
¹
²
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(webappendix p 4) or endometrial cancer incidence (data 
not shown). There were highly signiﬁ cant recurrence 
reductions both in the six trials with no chemotherapy 
(RR 0·56 [0·04]) and in the 14 trials of chemotherapy plus 
tamoxifen versus the same chemotherapy alone (RR 0·67 
[0·04]), with a slightly greater eﬀ ect of tamoxi fen in those 
with greater degrees of ER positivity in both trial categories 
(data not shown). For patients receiving chemotherapy, 
tamoxifen was of further beneﬁ t whether it started 
concurrently with the chemotherapy (RR 0·62 [0·06]) or 
after it (RR 0·71 [0·05]). The slight superiority of starting 
concurrently was, however, not signiﬁ cant, and these 
tamoxifen trials did not randomise timing. In all 
regimens, tamoxifen had a substantial eﬀ ect (ﬁ gure 4).
The proportional risk reductions were slightly, but not 
signiﬁ cantly, greater at older ages, but beneﬁ ts were 
substantial and consistent for women in each age range 
(including the many with entry age <45 years [and the few 
with entry age ≥70 years: 41 recurrences vs 68 recurrences, 
2p=0·001]). Nodal status, tumour grade, and diameter 
did not materially aﬀ ect proportional risk reductions. 
They were, however, importantly predictive of the 
absolute risk without tamoxifen, and hence of the 
absolute beneﬁ t of giving tamoxifen. Local recurrence, 
contralateral breast cancer (generally new primary), and 
distant recurrence were all substantially reduced by 
tamoxifen (each p<0·00001).
The proportional eﬀ ects on recurrence rates diﬀ ered 
between diﬀ erent time periods (ﬁ gure 4). Recurrence was 
reduced by more than half during the ﬁ rst 2 years (when 
almost all those allocated treatment would have been 
partially or fully treated) and by almost half during the 
next 3 years. During years 5–9 after randomisation there 
was (in all but two trials23–26) no diﬀ erence in adjuvant 
tamoxifen use between the treatment and control groups, 
yet the recurrence rate was still almost a third lower in 
those originally allocated tamoxifen (RR 0·68 [0·06], 
p<0·0001). After year 10, recurrence rates were similar 
(RR 0·97 [0·10]) in the two groups, indicating no loss after 
year 10 of the gains during years 0–9. 
Figure 5 shows 15-year results for recurrence and breast 
cancer mortality in all women with ER-positive disease. 
Remarkably, the yearly rate of breast cancer mortality was 
reduced by about a third (RR 0·70 [0·05], p<0·00001) 
throughout the ﬁ rst 15 years after randomisation, with 
highly signiﬁ cant extra beneﬁ t during each of years 0–4 
(RR 0·71 [0·05], 95% CI 0·62–0·80), years 5–9 
(0·66 [0·05], 95% CI 0·58–0·75), and years 10–14 
(0·68 [0·08], 95% CI 0·56–0·83), each p<0·00001 
(ﬁ gure 5, webappendix p 4). The absolute mortality 
diﬀ erence was only 3% (9% vs 12%) at year 5, by which 
time trial treatment had ended (in all except the few 
patients re-randomised to continue after year 5), but it 
was three times as great (24% vs 33%) by year 15. 
In ER-positive disease, the reductions in recurrence 
and mortality during years 0–4 were almost as great in 
trials of only 1–2 years as in trials of about 5 years of 
tamoxifen (webappendix pp 2, 18–23). However, the 
reductions in recurrence during years 5–9 were greater 
in trials of about 5 years of tamoxifen than in trials of 
Figure 5: Eﬀ ects of about 5 years of tamoxifen on the 15-year probabilities of recurrence and of breast cancer mortality, for ER-positive disease
Outcome by allocated treatment in trials of about 5 years of adjuvant tamoxifen. Event rate ratio (RR) is from summed log-rank statistics for all time periods. Gain 
(and its SE) is absolute diﬀ erence between ends of graphs. ER=oestrogen receptor. O–E=observed minus expected, with variance V. 
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6·71 (1466/21 862)
0·53 (SE 0·03)
–343·3/535·1
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0·68 (SE 0·06)
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2·06 (220/10 657)
2·11 (182/8620)
0·97 (SE 0·10)
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Recurrence Breast cancer mortality
Years 0–4 Years 5–9 Years 10–14 Year 15+ Years 0–4 Years 5–9 Years 10–14 Year 15+
Control
46·2%
33·0%
≈5 years 
tamoxifen
RR 0·61 (95% CI 0·57–0·65)
Log-rank 2p<0·00001
15-year gain 13·2% (SE 1·1)
Control
33·1%
23·9%
≈5 years 
tamoxifen
RR 0·70 (95% CI 0·64–0·75)
Log-rank 2p<0·00001
15-year gain 9·2% (SE 1·0)
10 645 women (100% ER positive, 44% node positive, 51% chemotherapy) 10 645 women
25·1%
17·9%
8·6%
11·9%
40·1%
25·9%
16·4%
28·7%
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only 1–2 years of tamoxifen. Although 1–2 years of 
tamoxifen had little further eﬀ ect on recurrence it had 
some further eﬀ ect on mortality after year 5, although 
smaller than that of about 5 years of tamoxifen 
(webappendix p 2). 
The table shows, for women with ER-positive disease, 
eﬀ ects on cause-speciﬁ c mortality and on second cancer 
incidence before any recurrence of the original breast 
cancer. (Eﬀ ects on diseases other than breast cancer were 
not materially aﬀ ected by ER status; webappendix 
pp 11–17.) Because tamoxifen delayed or prevented recur-
rence, those in the tamoxifen groups spent longer than 
controls at risk of death without recurrence (56 747 vs 
48 876 woman-years). Hence, absolute numbers of deaths 
before recurrence in treatment and control groups are 
not directly comparable, but log-rank analyses make due 
allowance for this imbalance.
The main life-threatening side-eﬀ ects of tamoxifen are 
uterine cancer and thromboembolic disease.1,27 In ER-
positive disease (mean 10 years of follow-up) there were 
nine deaths in the tamoxifen group versus one in the 
control group from uterus (excluding cervix) cancer and 
six versus no deaths from pulmonary embolus during 
the ﬁ rst 5 years (but no apparent excess afterwards). 
These included one versus zero deaths in 2962 versus 
3007  women younger than 55 years at entry, suggesting a 
10-year mortality of less than 0·1%, but 14 versus one 
death in 2386 versus 2289 in older women, suggesting a 
10-year mortality of 0·6% from these two side-eﬀ ects. 
Otherwise, we recorded no deﬁ nite diﬀ erences in mortality 
without recurrence. A non-signiﬁ cant excess of stroke 
deaths (three extra per 1000 women during the ﬁ rst 
15 years, none of which occurred during the treatment 
period) was balanced by a non-signiﬁ cant shortfall in 
cardiac deaths (three fewer per 1000 women during the 
ﬁ rst 15 years), so we recorded little net eﬀ ect on overall 
vascular mortality (webappendix p 14).
Tamoxifen increased uterine cancer incidence 
(excluding cervix cancer, RR 2·40 [0·32], p=0·00002), 
reduced contralateral breast cancer incidence by, in each 
age range, a larger absolute amount, and had no 
signiﬁ cant eﬀ ect on other types of cancer (table 1 and 
webappendix pp 16–17). These adverse and protective 
eﬀ ects persisted for some years after treatment ended 
(webappendix pp 9–13). The uterine cancer risk was 
strongly correlated with age, with little absolute risk for 
entry age younger than 45 years or 45–54 years, but for 
entry age 55–69 years 15-year incidence was 3·8% in the 
tamoxifen group vs 1·1% in the control group (absolute 
increase 2·6% [SE 0·6], 95% CI 1·4–3·8). By contrast, 
the absolute (and proportional) decrease in contralateral 
breast cancer was independent of age, with 15-year 
incidence of 6·5% vs 9·8% in ER-positive disease 
(absolute reduction 3·2% [0·8]). In ER-poor disease, the 
15-year incidence of contralateral disease was 7·1% in 
both treatment groups (absolute reduction 0·1% [1·1]).
In the hypothetical absence of breast cancer mortality, 
15-year probabilities of death from other causes in these 
trials were about 3% for entry ages younger than 45 years, 
6% for ages 45–54 years, and 20% for ages 55–69 years 
(similar to population mortality rates). Because this risk 
of a ﬁ fth for ages 55–69 years applied similarly to the 
tamoxifen and to the control group, in both groups 
15-year overall survival is a ﬁ fth smaller than 15-year 
breast cancer survival, so the 15-year gain is a ﬁ fth smaller 
for overall mortality than for breast cancer mortality 
(ﬁ gure 6); however, this ﬁ nding does not suggest any 
adverse eﬀ ect on mortality from causes other than breast 
cancer and the known side-eﬀ ects of tamoxifen. For entry 
age younger than 45 years, intercurrent mortality was 
low, there were no deaths from uterine cancer or 
pulmonary embolus in either group, and 15-year gains in 
overall mortality and in breast cancer mortality were 
similar (ﬁ gure 6).
Number of events 
(both groups)
 O–E Variance 
of O–E
Event RR (SE)   p value*
Death with or without recurrence
Death without recurrence 1117 4·9 258·6 1·02 (0·06) 0·79
Death with recurrence 2694 –224·5 620·2 0·70 (0·03) <0·00001
Any death 3811 –219·6 878·8 0·78 (0·03) <0·00001
Death without recurrence (selected groups of causes)
Vascular disease
Stroke 64 4·8 15·2 1·37 (0·30) 0·27
Pulmonary embolus† 12 2·5 3·0 2·30 (0·90) 0·25
Heart and other vascular 212 –6·1 50·1 0·89 (0·13) 0·43
Neoplastic disease
Uterus, excluding cervix‡ 10 3·2 2·2 4·28 (1·52) 0·07
Other neoplastic 187 –0·1 44·2 1·00 (0·15) 1·00
Other speciﬁ ed cause 312 4·6 71·0 1·07 (0·12) 0·63
Unspeciﬁ ed cause 320 –4·0 72·9 0·95 (0·11) 0·68
Second cancer incidence without previous recurrence (selected sites)
Contralateral breast, by age at entry (years) 
<45 110 –17·7 27·2 0·52 (0·14) 0·001
45–54 169 –18·8 41·5 0·64 (0·12) 0·004
55–69 268 –28·7 64·0 0·64 (0·10) 0·0001
≥70 17 0·1 4·1    ..    ··
All ages 564 –65·1 136·7 0·62 (0·07) <0·00001
Uterus, excluding cervix‡, by age at entry (years) 
<45 11 0·1 2·7 1·04 (0·62) 1·00
45–54 25 3·3 5·9 1·75 (0·55) 0·25
55–69 71 18·0 16·6 2·96 (0·44) 0·00002
≥70 1 0·8 0·2    .. ..
All ages 108 22·2 25·4 2·40 (0·32) 0·00002
Other or unknown site 606 2·6 143·6 1·02 (0·08) 0·86
Outcome by allocated treatment in trials of about 5 years of adjuvant tamoxifen. Webappendix p 17 shows results for all 
women, irrespective of ER status. O–E=observed minus expected, with variance V. RR=rate ratio. ER=oestrogen receptor. 
*Two-sided p value, calculated with correction for continuity. †Six deaths in the tamoxifen group versus no deaths in 
the control group from pulmonary embolus during years 0–4, two deaths in each group at years 5–9, and one death in 
each group at years 10+. ‡Nine versus one death (age at entry: 45–54 years, one vs none; 55–69 years, seven vs one; 
≥70 years, one vs none), and 83 versus 25 incident cases of uterine cancer, excluding cervix, as ﬁ rst event after entry. 
Table: Mortality by cause and incidence of second cancers, for ER-positive disease only
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Discussion
Longer follow-up of the trials of about 5 years of 
tamoxifen has greatly strengthened the evidence that 
substantially reduced mortality rates for breast cancer 
continue well beyond year 10, as a delayed eﬀ ect of the 
greatly reduced recurrence rates during years 0–9. It 
has also produced strong evidence of a substantial eﬀ ect 
even in disease that was only weakly ER positive 
Figure 6: Relevance of intercurrent mortality in women younger than 45 years and 55–69 years of age to the absolute eﬀ ects of tamoxifen on 15-year 
mortality, for ER-positive disease 
Outcome by allocated treatment in trials of about 5 years of adjuvant tamoxifen. Event rate ratio (RR) is from summed log-rank statistics for all time periods. Gain 
(and its SE) is absolute diﬀ erence between ends of graphs. ER=oestrogen receptor. O–E=observed minus expected, with variance V. 
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(10–19 fmol/mg), although not in disease that was 
wholly ER negative.
If all trials had been of exactly 5 years of tamoxifen 
versus no adjuvant tamoxifen, with full compliance in 
both groups, the net beneﬁ t would have been somewhat 
greater. A sixth of the treated patients in these trials of 
about 5 years of tamoxifen were allocated only 2–3 years 
of tamoxifen. In addition, of the patients allocated at least 
5 years of tamoxifen about 18% discontinued adjuvant 
treatment within 2 years. Both direct compari sons1 and 
indirect comparisons (webappendix p 2) show greater 
mortality reduction with about 5 years than with only 
about 2 years of tamoxifen. Moreover, particularly in the 
later trials, some controls with ER-positive disease might 
eventually have started adjuvant hormonal therapy 
anyway.28,29 Although the combined eﬀ ects of patient drop-
out and drop-in cannot be quantiﬁ ed exactly, the rate ratio 
for breast cancer death of 0·70 (SE 0·06) in the present 
meta-analyses of outcome by allocated treatment means 
that in ER-positive disease full compliance with 5 years of 
tamoxifen would reduce 15-year breast cancer mortality 
rates by at least a third, and probably somewhat more.
Measured ER status of the original primary tumour 
was the only patient or tumour characteristic recorded 
that strongly predicted tamoxifen eﬃ  cacy (ie, the propor-
tional RR). In women with ER-poor primary breast 
cancers, tamoxifen did not signiﬁ cantly reduce the overall 
recurrence rate, and did not seem to reduce the incidence 
of contralateral breast cancer. This apparently null result 
is, however, still consistent with the hypothesis that the 
proportional reduction produced by tamoxifen in the 
incidence of ER-positive contralateral disease is 
unaﬀ ected by the ER status of the original primary. (In 
the US SEER cancer registries30 only about half of the 
contralateral tumours arising more than a year after ER-
negative primary cancers are ER positive, compared with 
80% after ER-positive primary tumours.)
There appeared to be a fairly sharp cutoﬀ  in tamoxifen 
eﬃ  cacy with respect to the quantitative ER measurement, 
with little eﬀ ect at 4–9 fmol/mg and substantial beneﬁ t 
at 10–19 fmol/mg. (Reassuringly, ≥10 fmol/mg has been 
the criterion for ER positivity used in most trials, and by 
the EBCTCG.1) However, in view of the limitations of 
the ligand-binding ER assay method used in these 
trials,31,32 a sharp eﬃ  cacy cutoﬀ  at a particular assay value 
is not plausible. Although the evidence of substantial 
beneﬁ t from tamoxifen at ER measurements of only 
10–19 fmol/mg is robust, the evidence of zero beneﬁ t at 
4–9 fmol/mg is not, because the CI for tamoxifen 
eﬃ  cacy in this subgroup is wide, despite more than 
10 000 woman-years of follow-up. 
If there is a continuous relation between the measured 
ER and the eﬃ  cacy of tamoxifen, and the sharp cutoﬀ  was 
attributable mainly to chance, then detailed re-examination 
of these trial results is unlikely to provide clariﬁ cation. 
The most appropriate use of the trial ﬁ ndings might be 
to conclude from them the remarkable importance of 
pre vention of any stimulation of breast cancer cells by any 
functional ER in those cells, and the need to use sensitive 
and reliable ER assay methods in future patients.
Contemporary assessment of ER status is generally by 
immunohistochemistry (percentage of tumour cells 
stained by anti-ER antibody). However, because there is 
good concordance between immunohistochemistry  and 
ligand-binding assays of ER positivity,31–35 the present 
ﬁ nding of a substantial eﬀ ect of tamoxifen even at 
relatively low levels of ER positivity is relevant to present 
practice. Guidelines for immunohistochemistry assays36 
recommend deﬁ nition of ER positivity as 1% or more 
cells staining, but with some uncertainty about whether 
to include the range 1–10%. However, few patients if 
tested properly have 1–10% cells staining,31,32 and a low 
cutoﬀ  minimises life-threatening false negative ER results 
due to technical error. Interpretation of marginally 
positive ER assays could in future be helped by ER gene 
expression assays. (Preliminary studies of new assay 
methods could, however, engender false negative claims 
about endocrine eﬀ ects in some ER-positive subgroup.37)
Given the ER status, the PR measurement did not seem 
to be importantly predictive of eﬃ  cacy. In disease 
recorded as ER positive there was substantial and highly 
signiﬁ cant beneﬁ t even if the sample was recorded as PR 
poor. The absolute recurrence reduction at 15 years 
seemed, if anything, somewhat greater in ER-positive 
PR-poor disease than in ER-positive PR-positive disease, 
perhaps because of the somewhat higher background 
risk of recurrence without treatment. Conversely, in 
disease reported to be ER poor, positive PR measurements 
did not identify a subgroup with signiﬁ cant beneﬁ t. 
There did seem to be some slight early beneﬁ t from 
tamoxifen in disease that was measured to be ER poor 
and PR positive but this ﬁ nding was not signiﬁ cant, and 
might be attributable to inclusion in this category of a 
few patients with false-negative ER assays. As assays 
improve, fewer breast cancers are reported as ER negative 
PR positive (4% in the early 1990s but only 1% in 
recent years in the SEER cancer registry data30). For the 
few patients still reported as ER negative PR positive, 
repeat testing on another tissue sample has been 
recommended34,36 to rule out a false-negative ER assay in 
a patient who could beneﬁ t from endocrine treatment.
Although age is not a strong independent correlate of 
distant recurrence or of tamoxifen eﬃ  cacy, being young 
is a major determinant of the gain in life expectancy from 
avoidance of distant recurrence. Worldwide, half of all 
patients with breast cancer are younger than 55 years 
when diagnosed.38 For premenopausal or perimenopausal 
women with ER-positive breast cancer, tamoxifen is a 
major hormonal treatment option (because ovarian 
function cannot be controlled by aromatase inhibitors), 
and there is little uterine cancer risk or excess risk of fatal 
pulmonary embolus from administration of tamoxifen 
before age 45 years or at ages 45–54 years.27 By contrast, 
for older women with an intact uterus the excess risk of 
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death from endometrial cancer or pulmonary embolus 
could well be about 1%.
The key quantitative ﬁ nding that is likely to be 
generalisable to future patients37 is the proportional risk 
reduction produced by about 5 years of tamoxifen in ER-
positive disease, which is roughly independent of age, 
nodal status, tumour grade, diameter, chemotherapy use, 
and timing of chemotherapy (concurrent or sequential). 
This ﬁ nding suggests that if chemotherapy was being 
given then the additional therapeutic eﬀ ects of giving 
tamoxifen were approximately independent of any 
therapeutic eﬀ ects of that chemotherapy (a conclusion 
strongly reinforced by meta-analyses1 of the trials of 
chemotherapy, which found that the proportional risk 
reduction produced by chemotherapy was unaﬀ ected by 
whether tamoxifen was being given). 
Insofar as any of these factors substantially aﬀ ect 
absolute risk in women without tamoxifen, they 
substantially aﬀ ect the absolute reduction in risk 
produced by tamoxifen. Many treatment guidelines 
recommend endocrine treatment for disease with any 
degree of ER positivity.39 In accordance with this 
recommendation, our meta-analyses show a deﬁ nite and 
substantial protective eﬀ ect even at ER measurements of 
only 10–19 fmol/mg, and show that on average in all 
women with ER-positive disease full compliance with 
5 years of adjuvant tamoxifen would reduce the breast 
cancer mortality rate during the ﬁ rst 15 years after the 
start of treatment by at least a third, compared with no 
adjuvant endocrine therapy.
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